developed. Agreements were established with several information technology companies to embed NCCN-related content into various decision-assist tools for clinicians. Engagement with third-party payers expanded in an effort to influence coverage policy, provide case management training sessions, and voice related concerns of the NCCN Member Institutions.
As NCCN enters its third decade, the mission and the dedication/enthusiasm/ commitment of the membership and staff remain the same. Cancer treatment guidelines by definition are neither prescriptive nor static. The innumerable challenges before the entire oncology community-including economics, access to care, and globalization-warrant evolutionary changes within related organizations, including NCCN.
For its part, NCCN is integrating technologic advances to enhance the applicability of its products, including the guidelines. The development of cancer treatment regimen evidence blocks incorporating efficacy, safety, quality, and consistency of evidence and affordability, and the introduction of resource-stratified guidelines that consider the realities of limited resources around the world, are examples of NCCN's efforts to address some of these challenges. And more will come as this next decade-with NCCN's commitment to improve the safety, effectiveness, and efficiency of cancer care-unfolds.
